Background Current evidence suggests an important role of the interleukin‐6 (IL‐6) pathway
in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐related cytokine …

Objectives COVID-19 has become a global epidemic, and effective therapies have not been
discovered up to now. We conducted this study to explore the effectiveness and safety of …

Background Pneumonia with severe respiratory failure represents the principal cause of
death in COVID-19, where hyper-inflammation plays an important role in lung damage. An …

Background COVID-19 is an ongoing threat to society. Patients who develop the most
severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has …

Patients with coronavirus disease 2019 (COVID‐19) may develop severe respiratory
distress, thought to be mediated by cytokine release. Elevated proinflammatory markers …

This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the
treatment of severe coronavirus disease 2019 (COVID-19). Candidate studies up to 24 May …

Background Currently, the data regarding the effectiveness and safety of tocilizumab as
treatment for COVID-19 infection is still conflicting. This study aims to give clear evidence …

Abstract Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory
manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus …

Abstract Coronavirus disease 2019 (COVID‐19) due to infection with severe acute
respiratory syndrome coronavirus 2 causes substantial morbidity. Tocilizumab, an …

Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …